<DOC>
	<DOCNO>NCT00786812</DOCNO>
	<brief_summary>Maintain monitor long-term hematological cytogenetic response previously obtain patient participate [ CAMN107A2109 ] study</brief_summary>
	<brief_title>Study Treatment With Nilotinib Adult Patients With Imatinib - Resistant - Intolerant Chronic Myeloid Leukemia Blast Crisis , Accelerated Phase Chronic Phase</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1. patient currrently participate Novartis study CAMN107A2109 2. imatinib resistant intolerant Philadelphia chromosomepositive CML chronic ( CMLCP ) accelerate phase ( CMLAP ) blast crisis ( CMLBC ) 3. male female ≥18 year age 4. WHO Performance Status ≤ 2 5. patient must follow laboratory value : ALT AST ≤ 2.5 x ULN ≤ 5.0 x ULN consider due tumor 1 . Impaired cardiac function ; use therapeutic coumarin derivative 2. patient undergone major surgery recover side effect therapy within 15 day 3. patient pregnant breast feeding , adult reproductive potential employ effective method birth control 4. patient receive chemotherapy ≤ 1 week within 5 halflives last dose chemotherapy 5. , .patients receive imatinib dasatinib least 3 day prior begin study drug recover side effect therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>adult chronic myeloid leukemia</keyword>
	<keyword>imatinib</keyword>
	<keyword>nilotinib</keyword>
</DOC>